Melevodopa

Overview

Melevodopa (Levodopa methylester) is an orally active methylated prodrug of Levodopa ( HY-N0304 ), a dopamine precursor. When used in combination with Carbidopa ( HY-B0311 ) in an effervescent tablet formulation, Melevodopa inhibits motor fluctuations in Parkinson's disease. Melevodopa suppresses subcutaneous tumor growth, pulmonary metastasis proliferation, and primary mass invasiveness of melanoma. Melevodopa induces lipid peroxidation by increasing malondialdehyde levels in melanoma and improves the survival rate of melanoma-bearing mice. Melevodopa can be used in research related to Parkinson's disease (with motor fluctuations) and melanoma.

Application

Products | Products > Disease Areas > Melanoma | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug Intermediate | Products > Signaling Pathways > Dopamine Receptor

Product Information

• Catalog No.: HY-122278
• CAS No.: 7101-51-1
• Molecular Formula: C10H13NO4
• Molecular Weight: 211.21
• Purity: 99.98%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source